Close Menu

CareDx

The company is also continuing to expand its digital technology offering to help clinicians track their patients' health more easily.

The company reported $58.6 million in total revenues for the quarter and said testing services revenues rose 73 percent year over year.

The researchers hope that donor-derived cell-free DNA testing to monitor rejection can help relieve racial disparities in heart transplant outcomes.

The company said it will use the net proceeds from the offering for working capital and general corporate purposes.

CareDx expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.

The test will identify more than 100 pathogens, as well as drug resistance in viruses and bacteria.

CareDx first sued Natera in March 2019 for infringing two of its patents, then amended the suit a year later to add a third patent.

The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.

The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all fell in October.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.